TrialBDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
Trial details
- Registry ID
- NCT04819373
- Phase
- Phase 2
EIKN
Eikon Therapeutics
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
4Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid TumorsNCT04819373 | Eikon Therapeutics | Phase 2 | Completed | 2023-04-01Actual |
| A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCNCT06246110 | Eikon Therapeutics | Phase 2 | Active not recruiting | 2026-12Estimated |
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.NCT06697301 | Eikon Therapeutics | Phase 2, Phase 3 | Recruiting | 2035-12Estimated |
| A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.NCT07365319 | Eikon Therapeutics | Phase 2, Phase 3 | Recruiting | 2035-12-31Estimated |
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Trial details
- Registry ID
- NCT06246110
- Phase
- Phase 2
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Trial details
- Registry ID
- NCT06697301
- Phase
- Phase 2, Phase 3
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Trial details
- Registry ID
- NCT07365319
- Phase
- Phase 2, Phase 3
Latest recorded trial changes
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
NCT06246110 · Eikon Therapeutics
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
NCT07365319 · Eikon Therapeutics
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting